Highlights

  • Island Pharmaceuticals has commenced GMP manufacture of Galidesivir active pharmaceutical ingredient, with production beginning on 1 October 2026.
  • The first 5kg GMP batch is targeted for completion by the end of October and is intended for an approved emergency-use program in Uganda.
  • A second 5kg batch is scheduled for completion by late November to support broader Ebola development and a pivotal Marburg non-human primate study.
  • The Manufacturing program also includes analytical validation, reference-standard preparation and stability studies.

Island Pharmaceuticals Limited (ASX:ILA) is an Australian antiviral Drug Development and biodefence company focused on therapies addressing viral diseases, public-health needs and biosecurity threats. Its development portfolio includes ISLA-101 and Galidesivir, a clinical-stage broad-spectrum antiviral with activity across more than 20 RNA viruses. The company has now moved Galidesivir into GMP manufacturing, establishing drug Supply for planned Ebola and Marburg development programs.

First Galidesivir GMP Batch Enters Production

Island reported that GMP manufacturing of Galidesivir active pharmaceutical ingredient began on 1 October at PI Health Sciences. The manufacturing campaign marks the transition of its expanded Galidesivir program into physical production.

The first batch is expected to produce 5kg of GMP-grade API by the end of October 2026. Island has earmarked this material for its approved emergency-use program in Uganda during the ongoing Bundibugyo Ebola outbreak.

After API production is completed, additional finishing, vialing and packaging work will be required before the product can be shipped for investigational therapeutic use. The proposed deployment will operate under the World Health Organization's Monitored Emergency Use of Unregistered and Investigational Interventions framework.

Emergency Program Could Generate Human Clinical Data

The emergency-use program is intended to involve prospective collection of clinical, safety and virological data from patients treated with Galidesivir.

This represents a different evidence stream from the company's existing preclinical work. Island stated that Galidesivir already has human clinical experience as well as historical efficacy data from non-human primate models of Ebola and Marburg virus disease.

The company is seeking to build on that development history through two parallel pathways: prospective human data collection in Ebola under the MEURI framework and controlled non-human primate studies in Marburg under the U.S. Food and Drug Administration's Animal Rule pathway.

The announcement does not provide efficacy outcomes from the current emergency-use program because treatment and data collection have not yet been completed.

Second 5kg Batch Supports Marburg Development

Island is targeting completion of a second 5kg GMP API batch by the end of November 2026.

This material is intended to support the company's broader Ebola development strategy as well as its planned pivotal Marburg non-human primate study. The Marburg program is being developed under the FDA Animal Rule, which provides a regulatory pathway for certain products where human efficacy studies are not ethical or feasible.

Together, the two planned campaigns represent 10kg of targeted GMP API production. The first allocation is aimed at near-term emergency-use requirements, while the second is directed toward additional development activity.

Manufacturing Program Extends Beyond API Production

The broader manufacturing program includes analytical method validation, preparation of reference standards and stability studies. These activities are intended to establish the manufacturing and quality framework required for continued Galidesivir development.

Island also stated that the program is designed to support potential outbreak deployment, future regulatory activity and possible government procurement. These remain prospective objectives rather than completed commercial agreements.

Galidesivir has previously benefited from more than US$70 million of U.S. Government investment, according to the company. Island is now using the current manufacturing campaign to create GMP-grade supply that can be used across its planned clinical and regulatory programs.

Ebola Outbreak Provides Immediate Development Context

The company cited World Health Organization data showing that, as of 27 September 2026, the Bundibugyo Ebola outbreak had resulted in 8,137 confirmed cases and 3,926 confirmed deaths. This equates to a confirmed case fatality ratio of approximately 48%.

Island noted that there is no approved specific treatment for Bundibugyo Ebola virus disease, forming the public-health context for the planned investigational deployment of Galidesivir.

Key Takeaway

Island Pharmaceuticals Limited (ASX:ILA) has moved Galidesivir into GMP production, with two 5kg batches planned across October and November 2026. The first batch is intended for an Ebola emergency-use program in Uganda, while the second is earmarked for broader Ebola development and a pivotal Marburg non-human primate study. The next major milestones are completion of manufacturing, shipment preparation and subsequent generation of clinical and preclinical data.